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Abstract
Background: Severe anaemia (haemoglobin < 6 g/dL) is a leading cause of recurrent hospitalisation in African
children. We investigated predictors of readmission in children hospitalised with severe anaemia in the TRACT trial
(ISRCTN84086586) in order to identify potential future interventions.
Methods: Secondary analyses of the trial examined 3894 children from Uganda and Malawi surviving a hospital
episode of severe anaemia. Predictors of all-cause readmission within 180 days of discharge were identified using
multivariable regression with death as a competing risk. Groups of children with similar characteristics were
identified using hierarchical clustering.
Results: Of the 3894 survivors 682 (18%) were readmitted; 403 (10%) had ≥2 re-admissions over 180 days. Three
main causes of readmission were identified: severe anaemia (n = 456), malaria (n = 252) and haemoglobinuria/dark
urine syndrome (n = 165). Overall, factors increasing risk of readmission included HIV-infection (hazard ratio 2.48
(95% CI 1.63–3.78), p < 0.001); ≥2 hospital admissions in the preceding 12 months (1.44(1.19–1.74), p < 0.001);
history of transfusion (1.48(1.13–1.93), p = 0.005); and missing ≥1 trial medication dose (proxy for care quality)
(1.43 (1.21–1.69), p < 0.001). Children with uncomplicated severe anaemia (Hb 4-6 g/dL and no severity features),
who never received a transfusion (per trial protocol) during the initial admission had a substantially lower risk of
readmission (0.67(0.47–0.96), p = 0.04). Malaria (among children with no prior history of transfusion) (0.60(0.47–0.76),
p < 0.001); younger-age (1.07 (1.03–1.10) per 1 year younger, p < 0.001) and known sickle cell disease (0.62(0.46–0.82),
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p = 0.001) also decreased risk of readmission. For anaemia re-admissions, gross splenomegaly and enlarged spleen
increased risk by 1.73(1.23–2.44) and 1.46(1.18–1.82) respectively compared to no splenomegaly.
Clustering identified four groups of children with readmission rates from 14 to 20%. The cluster with the highest
readmission rate was characterised by very low haemoglobin (mean 3.6 g/dL). Sickle Cell Disease (SCD) predominated
in two clusters associated with chronic repeated admissions or severe, acute presentations in largely undiagnosed SCD.
The final cluster had high rates of malaria (78%), severity signs and very low platelet count, consistent with acute severe
malaria.
Conclusions: Younger age, HIV infection and history of previous hospital admissions predicted increased risk of
readmission. However, no obvious clinical factors for intervention were identified. As missing medication doses was
highly predictive, attention to care related factors may be important.
Trial registration: ISRCTN ISRCTN84086586.
Keywords: Severe anaemia, Readmission
Background
Severe anaemia (haemoglobin (Hb) < 6 g/dL) is a leading
cause of hospitalisation and mortality in children in sub-
Saharan Africa [1–4]. Guidelines developed by the
World Health Organization (WHO) encourage the
rational use of blood transfusion to preserve scarce
resources of donor blood and to reduce the risk of
transfusion-transmitted infections [5]. Specifically, they
recommend not to transfuse children who have a
haemoglobin between 4 and 6 g/dL without severity
features. They also recommend 20 ml/kg of whole blood
(or 10 ml/kg red cell concentrates) for all levels of
anaemia below Hb < 6 g/dL [6]. However, if standard
formulae are used to calculate volume required [7] this
would result in under-treatment children with profound
anaemia (haemoglobin < 4 g/dL) by ~ 30% as this volume
is insufficient to correct anaemia [8].
The evidence base supporting these guidelines is weak,
and as a result adherence is poor [8, 9]. A Cochrane re-
view published in 2000 included the only 2 African ran-
domised controlled trials (RCTs) [10, 11] conducted
(involving 114 and 116 children randomised to blood
transfusion or oral haematinics) concluded that there
was insufficient information on whether routinely giving
blood to clinically stable children with severe anaemia
reduces death or improves haematological correction
measured at 1 month, and indicated the need for a de-
finitive trial [12]. A subsequent study reporting on a
retrospective analysis of a multi-site observational study,
including over 25,000 children hospitalised with severe
malaria, reported an apparent benefit of blood transfu-
sion on in-hospital survival [13]. However, the findings
were challenged on the basis of selection bias since the
analysis did not account for the confounding effect of
time of death [14]. Death in children with severe malar-
ial anaemia often occurs within hours of admission [15],
including children awaiting a transfusion, as previously
demonstrated [8].
The aetiology of severe anaemia is frequently multi-
factorial, including potentially treatable co-morbidities
such as malaria, bacteraemia and multiple vitamin
deficiencies - key determinants of outcome [3] that
are not addressed in current treatment guidelines.
Outcomes remain unsatisfactory with high rates of re-
ported in-hospital mortality in cohort studies (9–10%)
[2, 3], and high additional mortality (8%), anaemia
relapse (6%) and re-admission (17%) in the 6-months
post-discharge [4]. The poor outcomes and recurrent
morbidity of children with severe anaemia warranted
a definitive trial to establish best transfusion and
treatment strategies to prevent both early and delayed
mortality and relapse. The TRACT trial (ISRC
TN84086586) was designed as a multicentre trial,
which enrolled 3983 children with severe anaemia
from four centres in Uganda and Malawi, to investi-
gate four different interventions to reduce the burden
of morbidity/mortality. The specific hypotheses were
(1) whether an immediate blood transfusion in chil-
dren with uncomplicated severe anaemia (Hb 4-6 g/dl)
would improve outcomes, (2) whether 30mls/kg ver-
sus 20mls/kg whole blood (or 15mls/kg vs 10mls/kg
red cell concentrate) might improve outcomes, de-
fined for both transfusion randomisations as mortality
to day 28 (primary outcome) and day 180, and the
need for additional transfusions and relapse of severe
anaemia [16] and (3) whether multivitamin multimin-
eral supplements (MVMM) using ‘Sprinkles’ formula-
tion [17] vs iron and folate (standard of care) given
for 3 months post-discharge and (4) whether infection
prophylaxis cotrimoxazole for 3 months post-discharge
vs no cotrimoxazole would reduce mortality and read-
missions to day 28 (primary outcome) and day 180.
The transfusion trial results, published in two linked
manuscripts in 2019 [18, 19], demonstrated that an
immediate transfusion is not required in children with
uncomplicated severe anaemia (Hb 4-6 g/dL without
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severity features), as long as children are monitored
for progression to the development of severe and/or
complicated anaemia during their initial hospital stay;
such progression occurred in 49% of participants in
the control arm, who then received a transfusion trig-
gered by the development of new signs of clinical se-
verity or a drop in haemoglobin level to less than 4 g/
dL [18]. The receipt of an immediate transfusion or
no immediate transfusion did not predict longer term
mortality or readmission to hospital. In children with
severe anaemia who received a larger volume of
blood, 30mls/kg whole blood equivalent (experimen-
tal), versus the 20 ml/kg (recommended in the current
WHO guidelines) who did not have a fever (axillary
temperature ≤ 37.5 °C, measured at screening) halved
the number of deaths by 28 days (HR 0.43 (95%CI
0.27, 0.69)) [19]. Conversely, in children who were fe-
brile (> 37.5 °C) at screening 30mls/kg whole blood
equivalent almost doubled the risk of death in com-
parison to children who received the lower, 20 ml/
kg, volume (HR 1.91 (95%CI 1.04, 3.49; p-value for
heterogeneity of effect on mortality p = 0.00009).
The micronutrient and infection prophylaxis trials
were reported in a separate manuscript which dem-
onstrated that neither enhanced supplementation
with multivitamin multimineral versus iron and fol-
ate treatment nor co-trimoxazole prophylaxis im-
proved 6-month survival or readmission to hospital
[20].
One notable finding from the trial was the substantial
rate of readmissions in the 6 months post-discharge,
occurring in around 1 in 6 children. Here we investigate
cause-specific incidence and predictors of hospital re-




The TRACT trial recruited children from Uganda
(Mbale Regional Referral Hospital, Soroti Regional
Hospital, and Mulago National Hospital, Kampala)
and Malawi (Department/College of Medicine and
Malawi-Liverpool-Wellcome Trust Clinical Research
Programme, Blantyre). The sites were selected to
represent a diversity of malaria transmission. In East-
ern Uganda malaria endemicity is high and perennial
(Mbale and Soroti centers); in Kampala (Mulago)
Uganda malaria transmission is low; in Blantyre, in
Southern Malawi malaria endemicity is moderate and
highly seasonal. Enrolment began in September 2014
and completed in May 2017 when the full sample size
was achieved. The last patient was followed up in
November 2017.
Original trial design
Eligible children were aged 2 months to 12 years present-
ing to hospital with severe anaemia (Hb < 6 g/dL); chil-
dren with transfusions during the same admission, with
known malignancy, trauma or surgery as main reason
for admission, signs of bi-ventricular heart failure,
chronic diseases or exclusively breast-fed infants were
excluded [16]. The trial had two strata. Stratum A (com-
plicated severe anaemia) included children with a
haemoglobin < 6 g/dL with one or more severity fea-
tures/symptoms (reduced conscious level (coma or pros-
tration), respiratory distress, acute haemoglobinuria or
known sickle cell disease (SCD)) or a haemoglobin < 4 g/
dL (profound anaemia) irrespective of symptoms. Chil-
dren in stratum A were given immediate transfusion
randomised (ratio 1:1) to a volume of 30 or 20 mls/kg
whole blood (15 vs 10 mls/kg red cell concentrates, de-
noted as whole blood equivalent). Stratum (TRACT) B
(children with uncomplicated severe anaemia) included
children with a Hb 4-6 g/dL with no severity features/
symptoms who were randomised (1:1:2) to 30 or 20 mls/
kg whole blood (15 vs 10 mls/kg red cell concentrates)
or to no immediate transfusion (control: standard of
care). Children in the control arm could receive a trans-
fusion if the clinical severity criteria were met or Hb fell
below 4 g/dL [16]. At the same time, all children were
randomised using a factorial open-label design to receive
3 months post discharge cotrimoxazole prophylaxis or
not, and to 3 months of MVMM supplementation
(containing 10mg iron as microencapsulated ferrous
folate and 150 micrograms folic acid in addition to
vitamins A, B1 (thiamine), B2 (riboflavin), B3 (niacin),
B6, B12, C, D, zinc, copper, selenium and iodine given
daily for all ages) versus standard treatment with iron
(either 25 mg iron for children < 2 years or 60 mg iron
for children ≥2 years) and folate (100–400 micrograms,
depending on the local formulation used as standard-of-
care at sites)) [20].
Study procedures
Children were managed on general pediatric wards; ven-
tilatory facilities were unavailable. Basic infrastructural
support for emergency care, patient monitors, bedside
hemoglobin, glucose and lactate point-of-care tests were
provided. Local blood transfusion services provided
blood free of charge, pre-screened for transfusion-
transmissible infections and prepared using standard
procedures, but without leucocyte reduction. Second
transfusions, if indicated in immediate-transfusion par-
ticipants, followed the originally-assigned randomized
volume. Children in the control group who developed de
novo severity criteria (hemoglobin < 4 g/dL or severity
signs above) were given 20ml/kg whole-blood equiva-
lent. Furosemide or other diuretics were not prescribed.
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Other treatments, including anti-malarials and antibi-
otics, followed national guidelines. For ethical reasons
screening and enrolment into the trial was halted when
there were no donor blood units were available from the
blood banks.
Data collection
A structured case report form was completed at screen-
ing and at reviews every 30 min during transfusion, then
regularly during admission. Haemoglobin was assessed
using Hb 301 system (Hemocue® AB, Angelholm,
Sweden) 8-hourly in the first 24 h and daily thereafter.
After discharge, children were actively followed up on
days 28, 90 and 180 post-randomisation for review of
clinical status and haemoglobin measurements. At all
follow up visits (including additional visits for illness) a
record of was made of any hospitalisations and at Day
28 and Day 90 the carer brought back any unused tab-
lets/sachets and these were recorded on a dedicated drug
adherence proforma. Most readmissions (hospitalisa-
tions) were to the study hospitals where trial clinicians
conducted a structured clinical assessment including
basic diagnostic work-up. Serious adverse events (SAE),
including re-admissions to the original or other hospi-
tals, were actively solicited at every assessment.
The ethics committees of Imperial College London
(ICREC 13–1-11), Makerere University, Uganda (SOM-
REC REF 2013–050), and the College of Medicine, Blan-
tyre, Malawi (COMREC P.03/13/1365), approved the
protocol. Where prior written consent from parents/
legal guardians could not be obtained, ethics committees
approved verbal assent with delayed written informed
consent as soon as practicable [21].
Outcomes
The primary outcome for this study was time from hos-
pital discharge to first readmission within the 180 day
follow up period. The incidence was estimated and pre-
dictors identified treating death before readmission as a
competing risk. Children were censored at the earliest of
date last known alive, or day 180 (6 months) from ran-
domisation. Secondary outcomes for these analyses were
time from discharge to first readmission for specific
causes (anaemia, malaria (malaria film or RDT positive),
or haemoglobinuria/dark urine syndrome (DUS)) [22].
As children could be re-admitted for multiple reasons
over the 6-months of follow-up, and individual readmis-
sions could also be for multiple reasons, when estimat-
ing incidence of readmission for each specific cause, we
treated death without readmission for that cause as a
competing risk, and any intervening admissions for other
causes were ignored.
Candidate predictors
All models adjusted for site (to control for minor differ-
ences in admission practices and management outside of
the protocol), uncomplicated vs complicated severe an-
aemia (determining whether or not children could be
randomised to no immediate transfusion) and whether
or not the child received a transfusion in the primary ad-
mission. Other candidate predictors (listed in Supple-
mentary Table 1) were from physical examination and
assessment of severity at screening, clinical history of
this illness, treatment in this illness, past history before
this illness, and details of the child’s family. Results from
the full blood count done at screening, transfusion blood
pack type and age of donor blood were also included, as
were the TRACT randomisations. Sickle cell disease sta-
tus (HbSS (sickle cell disease, SCD) or HbAS (sickle cell
trait) was obtained by batch genotyping stored admission
samples at the end of the trial. We subclassified the
HbSS genotype according to whether the child was
known to have SCD at discharge (children reported to
have SCD on admission, and 7 children found to have
SCD during their first admission). Binary variables repre-
senting time between admission and randomisation (<
24 h vs > 24 h) and treatment adherence (missed one or
more doses of MVMM, iron folate or cotrimoxazole by
28 days) were also included. A previous study found ad-
herence had a beneficial effect on HIV survival in chil-
dren even among those treated with placebo; therefore
we have used this variable as a proxy for quality of care
at home [23]. All data for the candidate predictors
related to the primary admission.
Statistical analysis of predictors of readmission
For the primary outcome, subhazard ratios for risk of re-
admission were estimated using a multivariable compet-
ing risks regression model, fitted using backwards
stepwise elimination on complete cases for those vari-
ables in Supplementary Table 1 with < 5% missing data
(including 2690 (69%) of 3894 children discharged alive
from their primary admission). Continuous variables
were modelled as fractional polynomials to allow for
non-linearity using Stata mfp (alpha = 0.05). The model
was refitted on cases that were complete on initially se-
lected variables, and then other excluded variables (in-
cluding those with > 5% missing data) were incorporated
one-by-one. All additional factors with p < 0.1 were in-
cluded in a second backwards elimination, retaining all
originally selected factors regardless of significance.
Interactions between the final included variables were
explored, and backwards elimination performed on all
interactions with p < 0.01. Variables with p < 0.05 in the
final model were considered significant.
For each secondary outcome, a competing risks model
included all variables from the all-cause model, then
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considered the other candidate variables as above. Fi-
nally models containing all factors identified as predic-
tors of malaria or anaemia admissions were fitted
together and a test of heterogeneity of effect on these
two different causes was performed for each factor using
stacked regression [24].
Risk score for readmission
A risk score was developed based on the final all-cause
readmission model as a mechanism to assess its overall
predictive ability. Each included factor was assigned an
integer value based on its hazard ratio, which was added
to the total score if that factor was present. A score of 1
was assigned to factors with a hazard ratio of approxi-
mately 1.3–1.5. Continuous variables were dichotomised
at a threshold approximating the same effect. Internal
validity was assessed using the area under the receiver
operating characteristic curve (AUROC) excluding
deaths, since these could not be predicted by the
competing risks model.
“Phenotypes” of children at risk for readmission
To investigate groups of predictors that co-occurred in
individual children presenting with severe anaemia, a
hierarchical cluster analysis was performed using Ward’s
linkage [25]. Clinical predictors in any of the all-cause or
cause-specific models with < 10% missing data were in-
cluded, with continuous factors rescaled so that all had
equal variance. As the focus was on clinical factors, vari-
ables relating to the trial process, such as site, random-
isation and blood pack, were not included. Strata (TRAC
T A or TRACT B- see above) was also excluded. How-
ever, respiratory distress and impaired consciousness
(used to define anaemia severity) were added. The Duda
Hart stopping rule [26] was used to determine the num-
ber of clusters, and comparisons of characteristics
between clusters was performed using chi-squared tests




From 17 September 2014 to 15 May 2017, 3983 eligible
children were randomised in TRACT. 89 (2%) died in
hospital, leaving 3894 (98%) children discharged alive
and included in these analyses.
Overall, 682 (18%) of these 3894 children were
readmitted during follow-up to 180 days, for a total of
921 admissions (Table 1). Four hundred and three (10%)
children were re-admitted on two or more separate oc-
casions. The cumulative incidence of readmission (treat-
ing death as a competing risk) was 6.4% at 30 days post-
discharge; 9.6% at 60 days; 13.2% at 90 days; and 18.3%
at 180 days. The most common reasons for readmission
were anaemia, malaria, other infections, and DUS/
haemoglobinuria (Table 1; each admission could be for
multiple reasons). In total, 456 (12%) children were re-
admitted for anaemia, 252 for malaria (6%) and 165 (4%)
for DUS. The cumulative incidences at 90 and 180 days
respectively were 8.5 and 12.1% for anaemia; 4.4 and
7.0% for malaria and 3.0 and 4.3% for DUS (Fig. 1).
Predictors of all-cause readmission using multivariable
regression
A variety of clinical factors at the start of the primary
admission for severe anaemia, underlying conditions and
factors relating to management of previous illness were
independently predictive of mortality (Table 2). The
model included 3384/3894 (87%) of children discharged
alive from their primary admission. Risk of readmission
increased with younger age (subhazard ratio (SHR) 1.07
(95% confidence interval 1.03–1.10) per 1 year younger,
p < 0.001) and was 2.5-fold higher in the 3% of children
who were HIV positive (SHR 2.48 (1.63–3.78), p <
0.001). In contrast, children with known sickle cell
disease had a 38% lower risk of readmission (SHR 0.62
(0.48–0.82), p = 0.01), with no evidence of variation in
risk across the other SCD categories. Risk was also
greater among children with two or more hospital
admissions in the past year (SHR 1.44 (1.19–1.74), p <
0.001) and those who had received a blood transfusion
prior to this illness (SHR 1.48 (1.13–1.93), p = 0.005).
Presenting with chest indrawing at admission (SHR 1.36
(1.09–1.71), p = 0.01) or splenomegaly (SHR 1.26 (1.06–
1.50) for enlarged, 1.47 (1.10–1.97) for gross, p = 0.01)
also led to a greater risk of readmission, while children
presenting with diarrhoea had a lower risk (SHR 0.71
(0.54–0.93), p = 0.01). Children admitted with malaria
(positive rapid diagnostic test (RDT) or blood slide) who
had not had a blood transfusion before this illness had a
lower risk of readmission (SHR 0.60 (0.47–0.76), p <
0.001) whereas those with malaria who had been trans-
fused before had a higher risk of readmission (SHR 1.58
(1.22–2.04); heterogeneity p < 0.001). Risk was also
higher in children who had a longer stay in hospital in
their primary admission (SHR 1.03 (1.00–1.06) per day
longer, p = 0.04). Finally, having missed one or more
doses of MVMM, iron folate or cotrimoxazole by the 28
day follow up visit (considered as a proxy for quality of
care at home) was also associated with an increased risk of
readmission (SHR 1.43 (1.21–1.69, p < 0.001) (Table 2). Of
note, other factors did not add predictive power to this
model, in particular there was no evidence of independent
effects of last haemoglobin level recorded in the primary
admission (SHR 0.98 (0.94–1.03) per g/dL higher, p =
0.47); nutritional status (SHR 1.01 (0.94–1.07) per 1 z-
score higher weight-for-age, p = 0.85); or transfused blood
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pack type (SHR 0.85 (0.70–1.03) for red cell concentrates
vs whole blood, p = 0.10).
Predictors of anaemia, malaria and DUS readmissions
using multivariable regression
Factors found to significantly increase the risk of readmis-
sion for anaemia in addition to the all-cause model were a
lower haemoglobin at screening in their primary admis-
sion (1.16 (1.05–1.29) per g/dL lower, p = 0.01) (Table 3).
For malaria readmissions, risk of readmission was doubled
in children from a rural homestead (SHR 2.19 (0.99–4.84),
p = 0.002) and children with a temperature gradient at
screening in their primary admission (SHR 2.07 (1.28–
3.35), p = 0.003). Children who were randomised to re-
ceive cotrimoxazole had a reduced risk of malaria re-
admission (SHR 0.75 (0.57–1.00), p = 0.05). Other
factors which reduced risk were a higher monocyte
count and receiving red cell concentrates rather than
a whole blood transfusion, while risk increased
among children who could walk unaided prior to ad-
mission (suggesting ambulant ‘older’ children are at
more risk of mosquito/malaria exposure) and those
with a higher platelet count (Table 3). For readmis-
sion with DUS, risk was higher among children with
haemoglobinuria in their primary admission (SHR
2.26 (1.37–3.71), p = 0.001), those with a positive
blood culture (SHR 3.25 (1.42–7.46), p = 0.01), and a
higher granulocyte count at screening for their
primary admission (SHR 1.35 (1.09–1.66) per 10 ×
109/L) (all p ≤ 0.01) (Table 3).
The test for heterogeneity in effect between anaemia
and malaria readmissions showed evidence of differ-
ences for several factors including age (p = 0.003); hav-
ing had malaria at the primary admission (p = 0.002);
trial strata and transfusion status (p = 0.003); and hav-
ing received oral antimalarials in the week before pri-
mary admission (p = 0.04) (Table 3).
Risk score for readmission
The integer score reflecting the combined effect of
the included factors on readmissions could theoretic-
ally range from 0 to 14 (Supplementary Table 2), al-
though the maximum score observed in the data was
10. The probability of readmission increased steadily
with increasing score (Fig. 2) with a 6% readmission
rate for children with a score of 3 and a 45% re-
admission rate among those with a score of 8. How-
ever, the discriminatory ability of this score was
relatively poor, with an AUROC of 0.68, excluding
deaths.
“Phenotypes” of children at risk for readmission
As the underlying causes of severe anaemia are hetero-
geneous our cluster analysis sought to understand com-
mon factors that may co-occur in children at the time of
the original admission that might predict readmission.
Table 1 Causes of readmission post initial admission for severe anaemia
Number (% of all readmissions)
Blantyre Mulago Soroti Mbale Total
Total readmissions 79 (100%) 174 (100%) 281 (100%) 387 (100%) 921 (100%)
Anaemia readmissions 55 (70%) 89 (51%) 165 (59%) 300 (78%) 609 (66%)
Haemoglobinuria/DUS readmissions 0 (0%) 8 (5%) 87 (31%) 125 (32%) 220 (24%)
Malaria readmissions 28 (35%) 31 (18%) 94 (33%) 129 (33%) 282 (31%)
Other infection readmissions: 20 (25%) 64 (37%) 26 (9%) 181 (47%) 291 (32%)
Sepsis 13 (16%) 29 (17%) 1 (0%) 153 (40%) 196 (21%)
Non-specific infection (fever) 0 (0%) 3 (2%) 0 (0%) 4 (1%) 7 (1%)
Respiratory 6 (8%) 20 (11%) 17 (6%) 32 (8%) 75 (8%)
Tuberculosis 0 (0%) 2 (1%) 0 (0%) 1 (0%) 3 (0%)
Gastrointestinal 1 (1%) 12 (7%) 3 (1%) 13 (3%) 29 (3%)
Bone infection 0 (0%) 1 (1%) 3 (1%) 1 (0%) 5 (1%)
Other 0 (0%) 5 (3%) 5 (2%) 1 (0%) 11 (1%)
Other non-infection readmissions: 10 (13%) 56 (32%) 39 (14%) 29 (7%) 134 (15%)
Sickle cell crisis 2 (3%) 24 (14%) 35 (12%) 11 (3%) 72 (8%)
Malignancy 7 (9%) 4 (2%) 2 (1%) 3 (1%) 16 (2%)
CNS 0 (0%) 2 (1%) 4 (1%) 2 (1%) 8 (1%)
Other 1 (1%) 27 (16%) 1 (0%) 11 (3%) 40 (4%)
Note: each readmission could have multiple causes and children could have multiple readmissions
There were 53/455 (12%) children with readmissions in Blantyre, 136/912 (15%) in Mulago, 215/1046 (21%) in Soroti and 278/1481 (19%) in Mbale
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Overall, four groups of children (“clusters”) were identi-
fied, comprising 47, 23, 21, and 10% of children with all-
cause readmission rates 20, 19, 15, and 14% respectively
(Supplementary Table 3). Details of cluster characteris-
tics are presented in Fig. 3 and Supplementary Table 3.
Most factors differed significantly across the four clus-
ters (p ≤ 0.01), with the exception of HIV (p = 0.08) and
positive blood culture (p = 0.16). Cluster 1 consisted of
children with very low haemoglobin (mean 3.6 g/dL) at
admission (with 60% having profound anaemia, Hb < 4
g/dL). A relatively high proportion had prior transfu-
sions and previous hospital admissions, and 44% had en-
larged spleen or gross splenomegaly, compared with 26–
37% in other groups. Cluster 2 consisted of young chil-
dren with a mean age of 10 months, a high proportion
(33%) of whom had undiagnosed sickle cell disease.
These children were more likely to present with diar-
rhoea (30%), and had low rates of haemoglobinuria (4%).
Cluster 3 had the largest proportion of sickle-positive
children (34%) and the highest previous healthcare usage
(48% had a prior transfusion, and 33% had two or more
hospital admissions in the past year). They were less
likely than other groups to present with respiratory dis-
tress or impaired consciousness. Finally, cluster 4 con-
sisted of children who were almost all sickle-negative
(91%), but had higher rates of malaria (78%), and im-
paired consciousness (28%). They also had a low platelet
count (mean 40 × 109/L), consistent with a severe mal-
aria phenotype [27]. This cluster had the lowest readmis-
sion rate (14%) but the highest proportion of deaths
post-discharge (10%).
Discussion
Overall, we found a high incidence of readmissions to
hospital among Ugandan and Malawian children follow-
ing an initial admission with severe anaemia. The re-
admission rate was highest in the first 30 days following
randomisation, at 6%, dropping to approximately 3% per
month thereafter; by 6-months 18% children had one or
more readmissions. We aimed to investigate predictors
of readmission to hospital and causes of readmissions.
Although the retention to 6 months follow-up was
Fig. 1 Cumulative incidence of readmissions from different causes (treating death as a competing risk)
Connon et al. BMC Public Health         (2021) 21:1480 Page 7 of 16
Table 2 Predictors of readmission
Predictor Readmitted (N = 682, col
% or median (IQR))
Not readmitted (N = 3212,







Sitea - Mbale 278 (41%) 1203 (37%) 1.00 1.00 0.25
Blantyre 53 (8%) 402 (13%) 0.61 (0.45–
0.82)
0.80 (0.57–1.12)
Mulago 136 (20%) 776 (24%) 0.79 (0.65–
0.97)
0.82 (0.65–1.03)
Soroti 215 (32%) 831 (26%) 1.08 (0.90–
1.29)
0.97 (0.79–1.19)
Age at primary admission (per year
younger)a
38.0 (17.0, 60.0) 34.0 (17.0, 62.0) 1.01 (0.98–
1.03)
1.07 (1.03–1.10) < 0.001
HIV positivea 26 (4%) 81 (3%) 1.52 (1.02–
2.28)
2.48 (1.63–3.78) < 0.001
Sickle status - AA 458 (67%) 2243 (70%) 1.00 1.00 0.01
AS 25 (4%) 99 (3%) 1.23 (0.82–
1.84)
1.16 (0.75–1.81)
SS, unknown at discharge 122 (18%) 486 (15%) 1.15 (0.94–
1.39)
0.95 (0.76–1.20)
SS, known at discharge 73 (11%) 353 (11%) 0.98 (0.77–
1.25)
0.62 (0.46–0.82)
Two or more hospital admissions in the last
year before primary admissiona
250 (37%) 651 (20%) 2.05 (1.76–
2.40)
1.44 (1.19–1.74) < 0.001
Received blood transfusion ever, prior to
this illnessa
341 (50%) 939 (29%) 2.17 (1.87–
2.52)
1.48 (1.13–1.93) 0.005
History of cough at primary admissiona 459 (67%) 1973 (61%) 1.27 (1.08–
1.49)
1.13 (0.95–1.35) 0.16
Indrawing on admissiona 118 (17%) 378 (12%) 1.51 (1.24–
1.84)
1.36 (1.09–1.71) 0.01
Splenomegaly on admissiona - Not
palpable
363 (53%) 2132 (66%) 1.00 1.00 0.01
Enlarged 248 (36%) 884 (28%) 1.57 (1.33–
1.84)
1.26 (1.06–1.50)
Gross 71 (10%) 190 (6%) 2.02 (1.57–
2.61)
1.47 (1.10–1.97)
Diarrhoea on admission 68 (10%) 437 (14%) 0.72 (0.56–
0.92)
0.71 (0.54–0.93) 0.01
Received oral antimalarials in last week
before primary admission
359 (53%) 1529 (48%) 1.21 (1.04–
1.41)
1.08 (0.92–1.27) 0.36
Malaria positive at primary admission, no
previous blood transfusion
195 (29%) 1533 (48%) 0.65 (0.52–
0.81)
0.60 (0.47–0.76) < 0.001
Malaria positive at primary admission,
previous blood transfusion
209 (31%) 539 (17%) 1.73 (1.40–
2.14)
1.58 (1.22–2.04) < 0.001
Randomised > 24 h after admissiona 37 (5%) 131 (4%) 1.28 (0.92–
1.77)
1.36 (0.96–1.93) 0.08
Strataa - TRACT A 452 (66%) 1884 (59%) 1.00 1.00 0.14
TRACT B, immediate transfusion 122 (18%) 655 (20%) 0.78 (0.64–
0.95)
0.93 (0.74–1.17)
TRACT B, triggered transfusion 69 (10%) 312 (10%) 0.91 (0.71–
1.17)
1.05 (0.79–1.40)
TRACT B, no transfusion 39 (6%) 361 (11%) 0.48 (0.35–
0.67)
0.67 (0.47–0.96)
Blood pack age (per week older)a 12.0 (7.0, 20.0) 12.0 (7.0, 17.0) 1.10 (1.03– 1.07 (0.99–1.15) 0.08
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excellent with very high ascertainment of vital status and
re-admission events, limited tests available for diagnos-
ing cause of readmissions meant we could only describe
a few with any certainty. We found strong evidence for
known predictors of increased risk of readmission, in
particular, younger age and HIV infection. Unsurpris-
ingly we also found a subgroup of children with repeated
hospitalisations and/or prior transfusions who were at
high risk of readmission. However, we did not identify
any obvious clinical factors for intervention, with the
possible exception of splenomegaly.
These results are broadly in agreement with a previous
study looking at recurrence of severe anaemia in 377
children aged 6–60months in Malawi [3]. Similar effects
of younger age, HIV, malaria, and history of previous
transfusion were found. In that study a history of jaun-
dice was found to be strongly predictive of a recurrence
of severe anaemia, but unlike our findings splenomegaly
was not found to be have an independent effect.
With respect to factors related to blood transfusion (and
health services) neither pack type (whole blood versus set-
tled cells) nor the length of storage of donor blood packs
had a significant effect on overall readmissions. We found
for malaria re-admissions (7% of total readmissions) that
there was a potentially lower risk of readmission with
transfusion using red cell concentrates (adjusted odds ra-
tio (AOR) 0.70 (0.49–1.00) p = 0.05). However, there was
no association with pack-type in those readmitted with
haemoglobinuria/dark water syndrome, a condition whose
underlying aetiology strongly implicates active or recent
malaria infection [22]; it therefore seems likely that this
may be a chance finding. We had previously reported that
neither whole-blood (44% of units transfused) or longer
storage-age of donor blood adversely affected 28-day or
180-day mortality [19]. Thus, since pack type neither in-
fluenced the risk of mortality or readmission, component
preparation, which has relatively recently been introduced
to blood transfusion services in sub-Saharan Africa (sSA)
at substantial cost, does not appear to be essential for safe
paediatric transfusion practice. However, since all blood
transfusions used in the TRACT trial were neither
leucocyte-reduced, nor irradiated, as is standard practice
in sSA [28], we were not able to establish whether this
may be a risk factor for readmission (or any other
transfusion-related immunomodulation (TRIM) adverse
outcomes [29]).
Children with uncomplicated severe anaemia (Hb 4-6
g/dL without severity features) who never received a
transfusion during the initial admission had 32% reduced
risk of readmission. However, this sub-group may not
have had the same baseline risk as the children rando-
mised to no immediate transfusion who subsequently re-
quired a transfusion; therefore we cannot say that risk
was reduced by not giving these children transfusions.
Finally, the ‘missed dose’ factor representing adherence
to randomised treatments, a putative proxy for quality of
care, was highly predictive, suggesting that caregiver-
related factors could also be important in driving read-
missions [23].
Clinical factors identified related to severity (chest
indrawing) and putatively malaria-endemicity (spleno-
megaly) were associated with increased risk of readmis-
sion to hospital. Gross splenomegaly (which we defined
in our study proforma as 5 cm or more below the costal
margin), was present in the original admission in 71
(10%) of the children who were readmitted and was
found to be one factor which appeared to discriminate a
subgroup at higher risk of readmission in cluster ana-
lysis. Children with a moderately enlarged spleen
(present in 248 (36%) of readmitted children) also had
increased risk of readmission compared to no palpable
spleen found at the initial admission (1.26 (1.06–1.50)).
Specifically, both the presence of gross splenomegaly or
moderately enlarged spleen increased the risk by 1.73
(1.23–2.44) and 1.46 (1.18–1.82) respectively for anaemia
readmissions. The presence of splenomegaly in a child
admitted with severe anaemia could therefore be a po-
tential target for future malaria prophylaxis intervention.
Among children with gross splenomegaly at the original
admission, 44% had HbSS (by genotype) compared to
the prevalence of HbSS (26%) in those without moderate
or no splenomegaly.
Table 2 Predictors of readmission (Continued)
Predictor Readmitted (N = 682, col
% or median (IQR))
Not readmitted (N = 3212,








Length of stay (per day longer)a 3.0 (2.0, 5.0) 3.0 (2.0, 4.0) 1.05 (1.03–
1.07)
1.03 (1.00–1.06) 0.04
Missed dose of MVMM, iron folate or
cotrimoxazole by 28 days
245 (36%) 925 (29%) 1.35 (1.15–
1.58)
1.43 (1.21–1.69) < 0.001
aselected by initial backwards elimination: retained in final model regardless of significance for control of confounding
Note: Denominators based on children with observed data; numbers missing are given in Supplementary Table 1. Site and receipt of transfusion were included in
all models. Final model included 3384/3894 (87%) children discharged alive and 609/682 (89%) readmitted children (exclusions due to missing data). All
continuous factors were selected as linear. SHR = sub-hazard ratio from competing risks model (treating death before readmission as a competing risk). TRACT A =
severe complicated anaemia (randomised to 30 vs 20 mls/kg transfusion). TRACT B = severe uncomplicated anaemia (randomised to immediate transfusion vs
triggered transfusion; those who ultimately received a transfusion are labelled “triggered transfusion” and those who did not “no transfusion”)
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HIV positive* 2.48 (1.52–
4.04)
< 0.001 0.85 (0.26–
2.76)
0.79 0.05 – –



















Two or more hospital admissions in the last
year before primary admission*
1.67 (1.33–
2.11)
< 0.001 1.24 (0.88–
1.74)










0.01 0.50 2.74 (0.94–
7.95)
0.06




0.49 0.94 1.21 (0.80–
1.83)
0.36




0.28 0.37 1.16 (0.66–
2.03)
0.60

















0.22 0.79 0.57 (0.27–
1.20)
0.14






0.71 0.04 1.19 (0.82–
1.73)
0.36




< 0.001 1.33 (0.77–
2.32)
0.31 0.002 1.71 (0.66–
4.43)
0.27






0.74 0.07 4.48 (1.70–
11.77)
0.94




0.79 0.09 1.70 (0.83–
3.45)
0.14
Strata* - TRACT A 1.00 0.29 1.00 0.08 0.003 1.00 0.47




















0.18 0.81 0.98 (0.83–
1.15)
0.81
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Splenomegaly is highly prevalent in children living in
malarious areas [30], but has generally been considered
as a relatively benign consequence of malaria exposure.
Gross (chronic splenomegaly) on the other hand is less
common and generally seen only in children exposed to
high levels of malaria transmission [31]; and may incorp-
orate a condition termed tropical splenomegaly syn-
drome or hyper-reactive malaria splenomegaly (HMS).
HMS is believed to be the result of chronic antigenic
stimulation derived from the malaria parasite and associ-
ated with elevated antimalarial antibodies [32]; genetic
factors may contribute to its development. Although
HMS is associated with poor long-term outcomes, there
have been few recent clinical trials of short or longer
term courses of antimalarial treatment/prophylaxis; most
were small, were conducted 2–3 decades ago and
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0.41 0.76 1.02 (0.95–
1.10)
0.60
Missed dose of MVMM, iron folate or





0.16 0.34 1.67 (1.16–
2.40)
0.01





Haemoglobin at admission (per g/dL lower) 1.16 (1.05–
1.29
0.01 0.83
Type of homestead - Urban 1.00 0.002 0.0031

















Monocytes (per 109/L) at admission 0.87 (0.77–
0.99)
0.03 0.035
Platelets (per 100 × 109/L) at admission 1.10 (1.02–
1.20)
0.02 0.11
Blood pack type- settled (vs whole) 0.70 (0.49–
1.00)
0.05 0.07





Liver > 2 cm below costal margin 1.47 (0.92–
2.38)
0.11
Positive blood culture at primary admission 3.25 (1.42–
7.46)
0.01





*selected by initial backwards elimination: retained in final model regardless of significance for control of confounding
** Blantyre and Mulago combined as there were no DUS readmissions in Blantyre
Note: Site and receipt of transfusion are included in all models. Anaemia: including 3381/3894 (87%) children discharged alive and 407/456 (89%) readmitted
children (exclusions due to missing data). Malaria: including 3317/3894 (85%) children discharged alive, and 223/252 (88%) readmitted children. DUS: including
2633/3894 (68%) children discharged alive and 121/165 (73%) readmitted children. SHR = sub-hazard ratio from competing risks model (treating death before
readmission for the specific cause as a competing risk). TRACT A = severe complicated anaemia (randomised to 30 vs 20 mls/kg transfusion). TRACT B = severe
uncomplicated anaemia (randomised to immediate transfusion vs triggered transfusion; those who ultimately received a transfusion are labelled “triggered
transfusion” and those who did not “no transfusion”)
HRs for anaemia readmission from stacked model:
1Type of homestead: semi urban 0.86 (0.53–1.41); rural 1.01 (0.66–1.54)
2Able to walk unaided before this illness at primary admission: 0.98 (0.68–1.42)
3Temperature gradient at primary admission: 1.04 (0.70–1.55)
4Cotrimoxazole randomisation- cotrimoxazole (vs no cotrimoxazole): 1.03 (0.83–1.27)
5Monocytes (per 109/L) at admission: 1.02 (0.94–1.11)
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focused on either chloroquine or proguanil [32]. The
most recent Cochrane review of intermittent preventative
antimalarial treatment (IPT) for children with severe an-
aemia [33] found no strong evidence that sulfadoxine-
pyrimethamine [34] or lumefantrine artesunate [35] reduced
readmissions/mortality in children hospitalised with severe
anaemia; of note, the review did not specifically address the
sub-group with splenomegaly.
Fig. 2 Proportion readmitted by risk score
Connon et al. BMC Public Health         (2021) 21:1480 Page 12 of 16
Fig. 3 Cluster characteristics
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The TRACT trial allowed us to test several hypotheses
with regard to sickle cell genotype status since all chil-
dren were genotyped and examined for four possible
genotype status (normal, sickle cell trait (HbAS), known
or unknown SCD). Whereas we might have expected
undiagnosed SCD to increase risk of readmission and
HbAS to reduce readmission compared to control, nei-
ther of these hypotheses were demonstrated. The latter
can be explained as the numbers of children with HbAS
were very few (only 4%), given background prevalence of
sickle cell of 15%. As previously demonstrated, the sub-
stantially lower prevalence of HbAS in children with se-
vere anaemia than the background suggest this is highly
protective of hospitalisation with severe anaemia [36],
owing to its high degree of malaria-specific resistance as
when considering malaria and anaemia readmissions
separately (Table 3; albeit not significant, potentially due
to lack of power). DUS or blackwater fever, a typical
triad of anaemia, passing of red or cola coloured urine
and jaundice in the presence of recent or active malaria
is a frequent cause for admission in Eastern Uganda
[22]. In re-analysis of the FEAST trial data using a case-
control design, we found no association between DUS
and G6PD deficiency, but the known malaria protective
genes (alpha thalassaemia and HbAS) were less common
in DUS cases, providing further support for an
aetiological role of malaria in DUS [22]. Even though
culture-proven bacteraemia was uncommon (4%), the
strong association of DUS readmission with a bacterial
infection on the primary admission may provide some
insights into the aetiological factors leading to recurrent
DUS. Additional predictors of anaemia and malaria
readmissions seemed to reflect intrinsic susceptibility to
these conditions, as reflected in severity of initial presen-
tation: for example, lower haemoglobin at the initial ad-
mission for anaemia readmission, and temperature
gradient and rural homestead for malaria readmissions.
Recurrent admission to hospital, a “revolving door” syn-
drome, is not unique to children with severe anaemia. In a
placebo-controlled trial of prophylactic cotrimoxazole in
1778 young (median age 11months) Kenyan children hos-
pitalised with severe and complicated malnutrition with
HIV, in the year following enrolment there 227 (14.5%)
deaths and 616 (35%) non-fatal hospital readmissions,
with cotrimoxazole providing no benefit to either end-
point [37]. For Kenyan children discharged following an
admission with severe pneumonia, the risk of post-
discharge mortality (and thus possible readmission) was
more than twice that of those admitted with other condi-
tions [38], with any degree of undernutrition as the key
risk factor in that study. While the authors suggested bet-
ter micro- and macronutrient support could improve out-
comes, this was not demonstrated in additional
randomised comparisons (vitamin and macronutrient
support) in TRACT [20]. Furthermore, in TRACT, al-
though few children had severe malnutrition (n = 75), nu-
tritional status was not a risk factor for readmission. A
multicentre placebo-controlled trial of 3 days of dihy-
droartemisinin–piperaquine (DHA-PPQ) malaria chemo-
prevention administered at 2, 6, and 10 weeks post
discharge to children admitted with severe anaemia and
were followed for 180 days [39]. DHA-PPQ reduced read-
missions by 70% (but not deaths) in the 3–14 weeks fol-
lowing discharge (i.e. up to 4 weeks following the last
dose) but not beyond this. This may have future potential
for reducing readmissions due to malaria in countries with
seasonal malaria but less impact where malaria transmis-
sion is perennial.
As severe anaemia has multiple potential causes, the
cluster analysis distilled this heterogeneous group into
four clusters. Of these, SCD predominated in clusters 2
(chronic repeated admissions) and 3 (acute form, largely
undiagnosed form). This further demonstrates the im-
portance of screening all children admitted with severe
anaemia for sickle cell disease, where it is endemic, since
children with known SCD were less likely to be
readmitted.
Limitations include possible omission of important
clinical factors in this study, since most data were re-
corded at screening or admission. Detailed health sta-
tus at discharge was not collected; for example, it is
possible that haemoglobin measured at discharge
would be a stronger predictor of readmission than
haemoglobin at screening or 48 h (the latest timepoint
tested consistently in all children). There were also
limited data available on social/family circumstances,
hence our use of “missed doses” of post-discharge
medication as a proxy for quality of care from care-
givers. There were also difficulties in assigning a pre-
dominant cause of readmission since each
readmission could have multiple causes, with many
children having combinations of malaria, anaemia,
DUS and other infections which may have been less
well investigated than during the primary admission.
In addition, there were some differences in how con-
ditions were described between sites and/or by clin-
ical staff (Table 1). In particular, a high number of
readmissions were attributed to sepsis; however, be-
cause one site never recorded this diagnosis, it was
not considered reliable enough for cause-specific ana-
lysis. As our goal was to try to identify factors which
could potentially be ameliorated by specific treat-
ments that could be tested in future trials, we consid-
ered a large number of predictors (Supplementary Table
1), arguing that restricting to a smaller number based on
current clinical opinion could miss important unknown
potential predictors aspects. Ultimately, the low predictive
power of our best-fitting model (AUROC only 0.68)
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suggests that the key determinants were not measured.
Given this we did not validate the readmission score in an
independent dataset.
Conclusions
This study adds to the evidence on hospital readmission
rates in children with severe anaemia and describes fac-
tors associated with increased risk of readmission for
three major causes - anaemia, malaria and DUS.
Overall, we were not able to identify specific predictors
of readmission that would be easily amenable to medical
intervention. However, the fact that previous receipt of
hospital services and carer adherence to medication were
some of the strongest predictors, highlights the need for
close follow up and support for parents with recurrently
sick children needing admission to hospital.
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